Open AccessDouble-blind controlled trial of the therapeutic effects of prostacyclin in patients with completed ischaemic stroke.
Author(s) -
J Huczyński,
E Kostka-Trąbka,
W Sotowska,
K Bieroń,
L Grodzińska,
A. Dembińska-Kieć,
E Pykosz-Mazur,
E Peczak,
Ryszard J. Gryglewski
Publication year - 1985
Publication title -
stroke
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.397
H-Index - 319
eISSN - 1524-4628
pISSN - 0039-2499
DOI - 10.1161/01.str.16.5.810
Subject(s) - medicine , prostacyclin , placebo , anesthesia , stroke (engine) , therapeutic effect , cerebral infarction , clinical trial , ischaemic stroke , ischemia , mechanical engineering , alternative medicine , pathology , engineering
In a pilot study, 26 patients with acute completed strokes (48 hours to 5 days after cerebral infarction) were randomly assigned to the prostacyclin (PGI2) or placebo groups. PGI2 sodium salt (Epoprostenol, Wellcome Research Laboratories and Upjohn Company) or its solvent (glycine buffer) were infused into the subclavian vein for six-hour periods in five courses separated by six-hour intervals. Prostacyclin was administered at a rate of 2.5-5.0 ng/kg/min. A significant alleviation of neurological deficits occurred 6 and 54 hours after the treatment in patients receiving prostacyclin. This improvement lost its statistical significance at the end of a two-week observation period. It is concluded that further modified controlled studies are required to evaluate the therapeutic usefulness of PGI2 in the treatment of patients with cerebral ischaemia.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom